These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2650076)

  • 1. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
    Barrett LV; Murphy JR; Strom TB; Kirkman RL
    Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy using interleukin-2 diphtheria toxin chimer prolongs murine allografts.
    Mackie JD; Pankewycz OG; Hassarjian R; Murphy JR; Kelley VE; Strom TB
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2718-9. PubMed ID: 2495680
    [No Abstract]   [Full Text] [Related]  

  • 3. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
    Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
    Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin-2-diphtheria toxin fusion protein prolongs murine islet cell engraftment.
    Pankewycz O; Mackie J; Hassarjian R; Murphy JR; Strom TB; Kelley VE
    Transplantation; 1989 Feb; 47(2):318-22. PubMed ID: 2493178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cytokine transcripts in pancreatic islet cell allografts during rejection and tolerance induction.
    Nickerson P; Pacheco-Silva A; O'Connell PJ; Steurer W; Kelley VR; Strom TB
    Transplant Proc; 1993 Feb; 25(1 Pt 2):984-5. PubMed ID: 8442291
    [No Abstract]   [Full Text] [Related]  

  • 6. DAB486-IL-2 (IL-2-toxin) in combination with low-dose RS-61443 (mycophenolate mofetil) prolongs murine thyroid allograft survival.
    Hullett DA; Landry AS; Eckhoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
    Transplant Proc; 1993 Feb; 25(1 Pt 1):756-7. PubMed ID: 8438470
    [No Abstract]   [Full Text] [Related]  

  • 7. Prolongation of murine thyroid allografts by interleukin 2 (DAB486)-toxin and RS-61443.
    Hullett DA; Landry AS; Eckoff DE; Nichols JC; Eugui EM; Allison AC; Sollinger HW
    Transpl Int; 1992; 5 Suppl 1():S487-9. PubMed ID: 14621855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of cytotoxin interleukin-2-pseudomonas exotoxin 66 on corneal allograft rejection in mice].
    Wu J; Yu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2152-5. PubMed ID: 19923053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
    Meneghetti CM; LeMaistre CF
    Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
    [No Abstract]   [Full Text] [Related]  

  • 10. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein.
    Kirkman RL; Bacha P; Barrett LV; Forte S; Murphy JR; Strom TB
    Transplantation; 1989 Feb; 47(2):327-30. PubMed ID: 2645719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
    Dutcher JP; Wiernik PH
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
    [No Abstract]   [Full Text] [Related]  

  • 12. Targeting of activated T-cells with natural cytotoxic antibodies via an IL2-hapten conjugate prolongs graft survival.
    Lussow AR; Fanget L; Gao L; Buelow R; Pouletty P
    Transplant Proc; 1996 Apr; 28(2):571-2. PubMed ID: 8623277
    [No Abstract]   [Full Text] [Related]  

  • 13. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
    Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
    Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
    Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
    Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation.
    Liu Y; Chen Y; Liu FQ; Lamb JR; Tam PK
    Transpl Int; 2008 May; 21(5):483-94. PubMed ID: 18266776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD4 monoclonal antibody-induced allograft survival is associated with a defect in interleukin-2-dependent T-cell activation.
    Pearson TC; Hamano K; Morris PJ; Wood KJ
    Transplant Proc; 1993 Feb; 25(1 Pt 1):786-7. PubMed ID: 8438480
    [No Abstract]   [Full Text] [Related]  

  • 17. Prolongation of murine cardiac allograft survival by the anti-interleukin-2 receptor monoclonal antibody AMT-13.
    Kirkman RL; Barrett LV; Koltun WA; Diamantstein T
    Transplant Proc; 1987 Feb; 19(1 Pt 1):618-9. PubMed ID: 3274828
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolongation of cardiac allograft survival following intraportal injection of donor antigen is inhibited by cyclosporine A.
    Farges O; Buffello D; Shi YM; Moufetier A; Bismuth H
    Transplant Proc; 1995 Aug; 27(4):2525-7. PubMed ID: 7652915
    [No Abstract]   [Full Text] [Related]  

  • 19. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
    Cai Y; Tang XD; Zhou PJ
    Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-level expression and purification of the recombinant diphtheria fusion toxin DTGM for PHASE I clinical trials.
    Frankel AE; Ramage J; Latimer A; Feely T; Delatte S; Hall P; Tagge E; Kreitman R; Willingham M
    Protein Expr Purif; 1999 Jun; 16(1):190-201. PubMed ID: 10336877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.